FDA Noxafil Approval Delayed By Last-Minute Label, Data Integrity Issues
Executive Summary
FDA overshot the user fee goal on Schering-Plough's Noxafil (posaconazole) to address labeling and data integrity issues that arose late in the review of the antifungal, FDA review documents indicate
You may also be interested in...
Schering-Plough’s Noxafil Clears FDA For Aspergillus Prophylaxis
Schering-Plough's Noxafil (posaconazole) is the first antifungal approved by FDA for the prevention of invasive fungal infections caused by Aspergillus species
Key To First-Cycle Approval Is To Meet Early And Often, Consultants Tell FDA
An independent analysis of FDA's first-cycle review performance provides support for the agency's request for additional funding for pre-submission meetings
PTC’s Upstaza Takes Gene Therapy Straight To Brain (And US FDA); Translarna To Return Mid-Year
In a year full of regulatory milestones for the firm, PTC Therapeutics hopes to set some approval precedents – and basically hopes its candidates have an easier time of it than they have had before.